533 related articles for article (PubMed ID: 23706982)
1. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.
Kalam K; Marwick TH
Eur J Cancer; 2013 Sep; 49(13):2900-9. PubMed ID: 23706982
[TBL] [Abstract][Full Text] [Related]
2. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
Gujral DM; Lloyd G; Bhattacharyya S
Breast; 2018 Feb; 37():64-71. PubMed ID: 29101824
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
Yun S; Vincelette ND; Abraham I
Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
[TBL] [Abstract][Full Text] [Related]
5. Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.
Abdel-Qadir H; Ong G; Fazelzad R; Amir E; Lee DS; Thavendiranathan P; Tomlinson G
Ann Oncol; 2017 Mar; 28(3):628-633. PubMed ID: 28028033
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
Ghasemi K; Vaseghi G; Mansourian M
J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
[TBL] [Abstract][Full Text] [Related]
8. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
9. Role of cardioprotective agents on chemotherapy-induced heart failure: A systematic review and network meta-analysis of randomized controlled trials.
Li X; Li Y; Zhang T; Xiong X; Liu N; Pang B; Ruan Y; Gao Y; Shang H; Xing Y
Pharmacol Res; 2020 Jan; 151():104577. PubMed ID: 31790821
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic Agents for Preventing Cardiotoxicity Induced Following Anticancer Agents: A Systematic Review and Meta-Analysis of Clinical Trials.
Keshavarzian E; Sadighpour T; Mortazavizadeh SM; Soltani M; Motevalipoor AF; Khamas SS; Moazen M; Kogani M; Amin Hashemipour SM; Hosseinpour H; Valizadeh R
Rev Recent Clin Trials; 2023; 18(2):112-122. PubMed ID: 36803186
[TBL] [Abstract][Full Text] [Related]
13. Heart failure from cancer therapy: can we prevent it?
Totzeck M; Mincu RI; Heusch G; Rassaf T
ESC Heart Fail; 2019 Aug; 6(4):856-862. PubMed ID: 31297946
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure.
Seicean S; Seicean A; Alan N; Plana JC; Budd GT; Marwick TH
Circ Heart Fail; 2013 May; 6(3):420-6. PubMed ID: 23425978
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysis.
Sayed A; Abdelfattah OM; Munir M; Shazly O; Awad AK; Ghaith HS; Moustafa K; Gerew M; Guha A; Barac A; Fradley MG; Abela GS; Addison D
Eur J Cancer; 2022 Jul; 169():82-92. PubMed ID: 35524992
[TBL] [Abstract][Full Text] [Related]
16. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function.
Shah R; Wang Y; Foody JM
Am J Cardiol; 2008 Jan; 101(2):217-22. PubMed ID: 18178410
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective Effects and Duration of Beta Blocker Therapy in Anthracycline-Treated Patients: A Systematic Review and Meta-analysis.
Xu L; Long Y; Tang X; Zhang N
Cardiovasc Toxicol; 2020 Feb; 20(1):11-19. PubMed ID: 31832905
[TBL] [Abstract][Full Text] [Related]
19. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.
Ohtani K; Fujino T; Ide T; Funakoshi K; Sakamoto I; Hiasa KI; Higo T; Kamezaki K; Akashi K; Tsutsui H
Clin Res Cardiol; 2019 Jun; 108(6):600-611. PubMed ID: 30367208
[TBL] [Abstract][Full Text] [Related]
20. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
